secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-08-03T13:35:12+00:00
Accession:  0001493152-26-035762
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine appoints Michael Grissinger to board of directors
----------------------------------------------------------

- Grissinger appointed as independent director effective August 3, 2026.
- Receives initial option grant of 2,000 shares and annual retainer of $55,000.
- Over 20 years at Johnson & Johnson in licensing and corporate development roles.
- Currently serves on boards of Aprea Therapeutics (APRE) and Adicet Bio (ACET).
- Chairman cites his dealmaking experience to advance pipeline and partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226035762/0001493152-26-035762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226035762/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer